Advertisement
UK markets closed
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • CRUDE OIL

    85.29
    -0.12 (-0.14%)
     
  • GOLD FUTURES

    2,402.40
    +19.40 (+0.81%)
     
  • DOW

    37,798.97
    +63.86 (+0.17%)
     
  • Bitcoin GBP

    50,624.16
    -294.27 (-0.58%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,865.25
    -19.77 (-0.12%)
     
  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     

What to Expect for AstraZeneca in Fiscal 2018

What to Expect for AstraZeneca in Fiscal 2018

AstraZeneca (AZN) has maintained its guidance for fiscal 2018. This expected growth in product sales is weighted towards the second half of the year, reflecting the impact of generic competition for Crestor in Europe and Japan and an increased revenue contribution from new medicines. AstraZeneca expects the sum of externalization revenue and other operating income and expenses to fall YoY (year-over-year).